Collegium Pharmaceutical
NASDAQ: COLLCanton, US · Virginia corporation · 488 employees on LinkedIn · 4 known investors
Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.
Founders & leadership
Board



Investors · 4
Reported raises · per SEC filings
Form D private placements$92.5M disclosed across 3 rounds · 2012–2018
▶$20MraisedNov 2018 · 1 investors · PharmaceuticalsRule 506(b)
- Michael HeffernanDirector
- David HirschDirector
- Garen BohlinDirector
- Shirley KuhlmannExecutive Officer
- Theodore SchroederDirector
- John A FallonDirector
- Alison B. FlemingExecutive Officer
- Gwen MelincoffDirector
- Gino SantiniDirector
- Scott DreyerExecutive Officer
- Joseph CiaffoniExecutive Officer, Director
- John FreundDirector
- Paul BrannellyExecutive Officer
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Nov 2018
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
▶$50MraisedMar 2015 · 18 investors · PharmaceuticalsRule 506(b)
- Gino SantiniDirector
- Eran NadavDirector
- John FreundDirector
- Patrick HeronDirector
- Garen BohlinDirector
- David HirschDirector
- Michael HeffernanExecutive Officer, Director
- Paul BrannellyExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Mar 2015
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
▶$22.5MraisedFeb 2012 · 12 investors · PharmaceuticalsRule 506(b)
- David HirschDirector
- Patrick HeronDirector
- Patrick FortuneDirector
- Michael HeffernanExecutive Officer, Director
- Stephen HoffmanDirector
- Offering amount
- $22.5M
- Amount sold
- $22.5M
- First sale
- Feb 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapCompanies competing with Collegium Pharmaceutical for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $472.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Collegium Pharmaceutical Initiates $50 Million Accelerated Share Buyback with Jefferies LLCkalkinemedia.com · Aug 2026
Collegium Pharmaceutical Reports Q2 2026 Results, Completes AZSTARYS Acquisition and Raises Full-Year Guidance | Quiver Quantitativequiverquant.com · Aug 2026Frequently asked questions
- What does Collegium Pharmaceutical do?
- Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.
- Who founded Collegium Pharmaceutical?
- Collegium Pharmaceutical was founded by Michael Heffernan.
- Who are Collegium Pharmaceutical's investors?
- Collegium Pharmaceutical's investors include APERTURE Venture Partners, EcoR1 Capital, Frazier Life Sciences, Longitude Capital.
- How much funding has Collegium Pharmaceutical raised?
- Collegium Pharmaceutical has disclosed $92.5M raised across 3 rounds.
- Where is Collegium Pharmaceutical headquartered?
- Collegium Pharmaceutical is headquartered in Canton, US.


